Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
Silo Pharma (Nasdaq: SILO) has partnered with WuXi AppTec, a leading global CRO, for a preclinical study of SPU-16, a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS). The study will examine the organ/tissue specificity of SPU-16 in an experimental autoimmune encephalomyelitis (EAE) protocol, the most common MS model.
SPU-16, developed under a license agreement with the University of Maryland, Baltimore, is designed to cross the blood-brain barrier and target damaged tissue and inflammation. It has shown potential to enhance therapeutic effects while reducing drug toxicity. The global MS drugs market is projected to grow from $21.2 billion in 2024 to $38.9 billion by 2032, with a 7.9% CAGR.
Silo Pharma (Nasdaq: SILO) ha stretto una partnership con WuXi AppTec, un importante CRO globale, per uno studio preclinico su SPU-16, un peptide mirato al sistema nervoso centrale (SNC) che agisce sulla sclerosi multipla (SM). Lo studio esaminerà la specificità degli organi/tessuti di SPU-16 in un protocollo di encefalomielite autoimmune sperimentale (EAE), il modello di SM più comune.
SPU-16, sviluppato sotto un accordo di licenza con l'Università del Maryland, Baltimore, è progettato per attraversare la barriera ematoencefalica e colpire i tessuti danneggiati e l'infiammazione. Ha dimostrato un potenziale per migliorare gli effetti terapeutici riducendo al contempo la tossicità dei farmaci. Si prevede che il mercato globale dei farmaci per la SM cresca da 21,2 miliardi di dollari nel 2024 a 38,9 miliardi di dollari entro il 2032, con un CAGR del 7,9%.
Silo Pharma (Nasdaq: SILO) se ha asociado con WuXi AppTec, un destacado CRO global, para un estudio preclínico de SPU-16, un péptido que se dirige al sistema nervioso central (SNC) enfocado en la esclerosis múltiple (EM). El estudio examinará la especificidad de órganos/tejidos de SPU-16 en un protocolo de encefalomielitis autoinmune experimental (EAE), el modelo de EM más común.
SPU-16, desarrollado bajo un acuerdo de licencia con la Universidad de Maryland, Baltimore, está diseñado para cruzar la barrera hematoencefálica y dirigirse a los tejidos dañados y la inflamación. Ha mostrado potencial para mejorar los efectos terapéuticos a la vez que reduce la toxicidad de los medicamentos. Se prevé que el mercado global de fármacos para la EM crezca de 21,2 mil millones de dólares en 2024 a 38,9 mil millones de dólares para 2032, con una tasa de crecimiento anual compuesta (CAGR) del 7,9%.
Silo Pharma (Nasdaq: SILO)는 글로벌 CRO인 WuXi AppTec와 협력하여 다발성 경화증(MS)을 목표로 하는 중추신경계(CNS) 호밍 펩타이드 SPU-16의 전임상 연구를 진행합니다. 이 연구는 가장 일반적인 MS 모델인 실험적 자가면역 뇌척수염(EAE) 프로토콜에서 SPU-16의 장기/조직 특이성을 분석할 것입니다.
SPU-16은 메릴랜드 대학교 볼티모어 캠퍼스와의 라이선스 계약에 따라 개발되었으며, 혈관-뇌 장벽을 통과하고 손상된 조직과 염증을 표적으로 삼도록 설계되었습니다. 이 약물은 약물의 독성을 줄이면서 치료 효과를 향상시킬 가능성을 보여주었습니다. 2024년에는 212억 달러에서 2032년까지 389억 달러로 성장할 것으로 예상되는 전 세계 MS 약물 시장은 7.9%의 연평균 성장률(CAGR)을 기록할 것으로 보입니다.
Silo Pharma (Nasdaq: SILO) a établi un partenariat avec WuXi AppTec, un CRO mondial de premier plan, pour une étude préclinique sur SPU-16, un peptide de ciblage du système nerveux central (SNC) visant la sclérose en plaques (SEP). L'étude examinera la spécificité des organes/tissus de SPU-16 selon un protocole d'encéphalomyélite auto-immune expérimentale (EAE), le modèle SEP le plus courant.
SPU-16, développé sous un accord de licence avec l'Université du Maryland, Baltimore, est conçu pour franchir la barrière hémato-encéphalique et cibler les tissus endommagés et l'inflammation. Il a montré un potentiel pour améliorer les effets thérapeutiques tout en réduisant la toxicité des médicaments. Le marché mondial des médicaments contre la SEP devrait passer de 21,2 milliards de dollars en 2024 à 38,9 milliards de dollars d'ici 2032, avec un taux de croissance annuel composé (CAGR) de 7,9 %.
Silo Pharma (Nasdaq: SILO) hat sich mit WuXi AppTec, einem führenden globalen CRO, zusammengetan, um eine präklinische Studie zu SPU-16, einem auf das zentrale Nervensystem (ZNS) abzielenden Homing-Peptid gegen Multiple Sklerose (MS), durchzuführen. Die Studie wird die Organ-/Gewebe-Spezifität von SPU-16 in einem experimentellen Verfahren der autoimmunen Enzephalomyelitis (EAE) untersuchen, dem gebräuchlichsten MS-Modell.
SPU-16, das unter einem Lizenzvertrag mit der Universität von Maryland, Baltimore, entwickelt wurde, soll die Blut-Hirn-Schranke überwinden und geschädigte Gewebe sowie Entzündungen gezielt ansprechen. Es hat ein Potenzial gezeigt, die therapeutischen Effekte zu verbessern und gleichzeitig die Medikamenten-Toxizität zu verringern. Der globale Markt für MS-Medikamente wird voraussichtlich von 21,2 Milliarden US-Dollar im Jahr 2024 auf 38,9 Milliarden US-Dollar bis 2032 wachsen, mit einer jährlichen Wachstumsrate (CAGR) von 7,9%.
- Partnership with WuXi AppTec, a leading global CRO, for preclinical study of SPU-16
- SPU-16 designed to cross blood-brain barrier and target damaged tissue and inflammation
- Potential to enhance therapeutic effects while reducing drug toxicity
- Global MS drugs market projected to grow from $21.2 billion in 2024 to $38.9 billion by 2032 (7.9% CAGR)
- None.
This partnership with WuXi AppTec marks a significant step for Silo Pharma in advancing their SPU-16 homing peptide for multiple sclerosis (MS). The preclinical study using the experimental autoimmune encephalomyelitis (EAE) model is important for validating the peptide's organ/tissue specificity. If successful, this could lead to a targeted drug delivery system that enhances therapeutic effects while reducing toxicity.
The potential of SPU-16 to cross the blood-brain barrier and target damaged tissue is particularly promising for MS treatment. However, investors should note that this is still in early stages and success in preclinical studies doesn't guarantee clinical efficacy. The projected growth of the MS drug market (
While this partnership is a positive development for Silo Pharma, investors should temper their expectations. As a developmental stage company, Silo is still far from commercialization and revenue generation. The agreement with WuXi AppTec, a reputable CRO, lends credibility to Silo's research efforts but doesn't guarantee success.
The MS drug market's projected growth to
Silo to advance homing peptide development for initial indication in multiple sclerosis
SARASOTA, FL, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into an agreement with WuXi AppTec (Hong Kong) Limited, a leading global contract research organization (CRO), for a preclinical small animal study of SPU-16, a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS). Silo Pharma is advancing the development of the SPU-16 liposomal homing peptide through a commercial evaluation license and option agreement with the University of Maryland, Baltimore (UMB).
The study will examine the organ/tissue specificity of the SPU-16 peptide in an experimental autoimmune encephalomyelitis (EAE) protocol, is the most commonly used experimental model for MS. The peptide’s proven ability to target inflamed epithelium suggests that it can be used as a targeted drug delivery tool to address inflammation in the spinal cord.
“We are excited to launch this new study of our novel CNS homing peptide under the management of WuXi AppTec, one of the largest CROs in Asia and globally,” said Silo CEO Eric Weisblum.1 “Designed to cross the blood-brain barrier and target damaged tissue and inflammation, SPU-16 has been shown to enhance the therapeutic effect of current and future therapeutics while decreasing the toxicity of the drugs. While we are currently investigating the peptide for MS, it could provide similar benefits for multiple neuroinflammatory pathologies.”
MS, a human inflammatory demyelinating disease, is one of the most widespread disabling neurological conditions of young adults.2 The global multiple sclerosis drugs market size is projected to grow at a compound annual growth rate (CAGR) of
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Silo’s research and development programs are conducted through collaborations with universities and independent laboratories. For more information, visit www.silopharma.com and connect on social media at LinkedIn , X , and Facebook .
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
1 BAIPHARM, Top 10 CROs With the Highest Revenues in 2023, April 2024
2 Healthline, Multiple Sclerosis: Facts, Statistics, and You
3 Fortune Business Insights, Multiple Sclerosis Drugs Market Size, Share & Industry Analysis…, July 2024
FAQ
What is the purpose of Silo Pharma's partnership with WuXi AppTec for SPU-16?
How does SPU-16 potentially benefit multiple sclerosis treatment?
What is the projected growth of the global multiple sclerosis drugs market according to Silo Pharma's press release?
What is the stock symbol for Silo Pharma mentioned in the press release?
